Filing Details
- Accession Number:
- 0001225208-10-021220
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-09-22 12:06:18
- Reporting Period:
- 2010-09-20
- Filing Date:
- 2010-09-22
- Accepted Time:
- 2010-09-22 12:06:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
901219 | Human Genome Sciences Inc | HGSI | In Vitro & In Vivo Diagnostic Substances (2835) | 223178468 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1191231 | H James Davis | 14200 Shady Grove Road Rockville MD 20850 | Exec. Vp, Gen Counsel & Sec. | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2010-09-20 | 26,000 | $9.35 | 114,739 | No | 4 | M | Direct | |
Common Stock | Disposition | 2010-09-20 | 26,000 | $30.01 | 88,739 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option - Right to Buy | Disposition | 2010-09-20 | 26,000 | $0.00 | 26,000 | $9.35 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
52,301 | 2012-12-11 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Charles Schwab effective 5/14/10.
- This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. Upon written consent by the Commission staff, the issuer or the security holder of the issuer will provide information regarding the number of shares sold at each separate price.
- These options have vested and are exercisable.